Collaboration key to delivering targeted medicines

REVOLUTIONIZING HEALTHCARE

Targeted medicine typically refers to a product that binds to a defined target to treat a specific subset of patients (1).
A targeted therapy can selectively target abnormal signaling pathways or biological processes underlying a given disease, offering treatment tailored to a patient’s genetic mutations or protein expression profiles (2).
They have proved particularly effective in the field of oncology, where targeted therapies such as Imatinib (Glivec) and trastuzumab (Herceptin) are improving the survival rate of patients with certain types of cancer (3, 4).
Precision medicine can span myriad drug classes, including small molecules, monoclonal antibodies, antibody-drug conjugates, radioligand therapeutic agents and immunotherapies, as well as cell and gene therapies (5).
Connecting the right treatment with the right patient is enabled by biomarkers and companion diagnostics (CDx), while artificial intelligence has proved invaluable in target identification.

MAKING THE RIGHT CONNECTIONS